Hikma Pharmaceuticals Shares Drop Amid Weaker Forecasts and Leadership Changes

Hikma Pharmaceuticals, a leading FTSE 100 company in the pharmaceuticals sector, has seen a significant decline in its share price following the announcement of weaker financial forecasts and the scrapping of medium-term guidance. The company, known for being one of the world’s largest manufacturers of generic drugs, has predicted revenues will rise by only 2 to 4 per cent, falling short of expectations set by market analysts.

The alteration in the company’s outlook resulted in a notable drop of 279 pence, which equates to a 16.9 per cent decrease in share value, closing at £13.73. This downturn comes in the wake of a leadership overhaul at Hikma, with Said Darwazah reinstated as chief executive after a brief tenure of Riad Mishlawi, who was promoted to the role less than six months prior.

Hikma’s financial guidance was initially presented at an investor event in May at its facility in Ohio. However, the company has since reduced its growth forecasts, a decision that has rattled investor confidence. The family remains the largest shareholder in Hikma, controlling a 27 per cent stake via their Darhold investment vehicle, which has been involved in managing share pledges amid the company’s stock decline.

The injectables division, which is the largest of Hikma’s three main business sectors, continues to face notable competition in the U.S. market. This includes challenges concerning high-value products such as testosterone and calcitonin, coupled with the impact of currency fluctuations and increased inventory provisions. Production delays at a new manufacturing facility in Bedford, Ohio, will push operational readiness to 2028.

To counteract these adverse conditions, Hikma plans to augment its investment in research and development as well as sales and marketing. This approach may, however, inhibit margin growth in the short term. A slight alleviation for stakeholders is found in the company’s decision to increase its total dividend by five per cent to 84 cents, along with a $250 million share buyback, signalling some level of confidence amidst the turmoil.